Autosomal Emery-Dreifuss muscular dystrophy is caused by mutations in the lamin A/C gene (LMNA) encoding A-type nuclear lamins, intermediate filament proteins of the nuclear envelope. Classically, the disease manifests as scapulo-humero-peroneal muscle wasting and weakness, early joint contractures and dilated cardiomyopathy with conduction blocks; however, variable skeletal muscle involvement can be present. Previously, we and other demonstrated altered activity of signaling pathways in hearts and striated muscles of Lmna H222P/H222P mice, a model of autosomal Emery-Dreifuss muscular dystrophy. We showed that blocking their activation improved cardiac function. However, the evaluation of the benefit of these treatments on the whole organism is suffering from a better knowledge of the performance in mouse models. We show in the present study that Lmna
INTRODUCTION
LMNA mutations cause an autosomal dominant inherited form of Emery-Dreifuss muscular dystrophy (EDMD) (1) . EDMD is characterized by the clinical triad of joint contractures that begin in early childhood, slowly progressive muscle weakness and wasting initially in a humero-peroneal distribution that later extends to the scapular and pelvic girdle muscles, and cardiac involvement that manifests as poor exercise tolerance, and congestive heart failure (2, 3) . Clinical variability ranges from early onset with severe presentation in childhood to late onset with slow progression in adulthood. Cardiac involvement usually occurs after the second decade (4) . LMNA encodes the A-type nuclear lamins (5) , which arise from alternative RNA splicing and are the constituents of nuclear lamina. Given the ability of mouse models to phenocopy various aspects of cardiovascular diseases, the use of mouse models has become critical to the study of cardiac biology, physiology, and novel therapeutics prior to translating findings to human. We largely contributed in understanding the metabolic and physiological mechanisms regulating cardiac function and energy balance in EDMD, both in animal models and in patient's tissues. These include abnormal regulation of the mitogenactivated protein kinase (MAPK) signaling cascade (6, 7) , altered actin dynamics (8) , altered Wnt/β-catenin signaling (9), fibrosis (10), NAD signaling (11) and AKT/mTOR signaling (12) . Despite the growing understanding of the pathogenesis of EDMD as well as the discovery of novel therapeutic for the disease (7, (9) (10) (11) (12) (13) , little is known on the overall benefit of these treatments on the performance of the animals. There is a need for more comprehensive ways of assessing disease progression and treatment efficacy. Traditional approaches to monitoring disease progression in preclinical models of muscular dystrophies are limited mostly to histological analyses and functional measurements of single fibers or muscle groups. However, none of these tests can assess systemic muscle function in a non-invasive approach consistent with clinical assessment in EDMD patients.
Respiration is a product of systemic skeletal and cardiac muscle function (14) . We here hypothesized that quantifying respiration during exercise would be a mean to studying systemic muscle function in a mouse model of EDMD, as it is commonly used to assess performance in humans (15) . During testing, cardiac output primarily drives the associated increase in oxygen consumption (VO 2 ) until peak oxygen consumption (VO 2 peak) and exhaustion is achieved. Combined measurements of exercise, respiratory performance and histological marker expression therefore provide a comprehensive, reliable, and powerful mean for assessing drug efficacy in a mouse model for EDMD, which in turn could help advance drug discovery.
RESULTS

Depressed left ventricular function in Lmna
H222P/H222P mouse model
To explore the role of A-type lamins in the development of EDMD, we studied a mouse model that display a Lmna mutation changing the histidine in position 222 into a proline (15 Figure 1A ) (8, 9, 16) . Left ventricular dilatation in Lmna H222P/H222P male mice at 6 months of age was demonstrated by histopathological analysis ( Figure 1B ). M-mode transthoracic echocardiography showed increased left ventricular end-systolic and end-diastolic diameters in Lmna H222P/H222P mice compared with wild type mice ( Figure 1B ). We showed a marked increased of myocardial fibrosis in heart from Lmna H222P/H222P male mice at 6 months of age, as observed by Sirius Red staining ( Figure 1C ).
Alteration of body composition in Lmna H222P/H222P mouse model
As the EDMD progresses further, skeletal muscle continues to be lost, which can result in weight loss. We assessed the body composition using DEXA lean/fat in Lmna H222P/H222P mice. We observed that Lmna H222P/H222P mice have a significant difference in body weight compared with wild type mice ( Figure 2A ). In 3-month-old Lmna H222P/H222P mice, the mean of body weight was 24.12g, while from wild type mice it was 26.66g. At 6 months of age, the mean of body weight was 24.94g for Lmna H222P/H222P mice, while it was 28.14g for wild type mice. Further complicating these issues are the changes in body composition that are linked to EDMD. We observed that Lmna 
Alteration of physical performance in Lmna H222P/H222P mouse model
We therefore asked whether we could assess the activity of Lmna H222P/H222P mice. Forced exercise on a treadmill was used to measure VO 2 peak. The VO 2 peak corresponds to both the cardiovascular system's functional limitation and the organism's aerobic capacity. Peak oxygen consumption has been previously validated to assess prognosis in patients with heart failure (17). We showed that Lmna H222P/H222P mice have a significant reduction in VO 2 peak, as well as relative VO 2 peak, compared with wild type mice at 3 and 6 months of age ( Figure 4A ). The ratio VCO 2 /VO 2 is the respiratory exchange ratio (RER), which can be used to determine the proportion of carbohydrates and fatty acid utilized during an activity. Peak RER has been used as an objective parameter of effort (18).
The Lmna H222P/H222P mice have a significant decreased RER at VO 2 peak ( Figure 4B ). The lower RER at VO 2 peak observed in Lmna H222P/H222P male mice indicates a higher level of lipid metabolism when compared with wild type mice. Importantly, there was a significant difference in the maximal speed and the running distance between the two genotypes ( Figure 5) ; thus, the decreased metabolic performance of Lmna H222P/H222P mice resulted to a change in physical activity.
We next tested whether interventions on mice could alter these parameters of effort. Given that the NAD + precursor -nicotinamide riboside (NR) supplemented diet was recently shown to have benefit on cardiac contractility in Lmna H222P/H222P mice (11), we next assessed in a pilot study the NR effect on physical and metabolic performances in Lmna H222P/H222P male mice. Since we recently reported an aberrant cardiac NAD + content, we first assessed the steady-state skeletal muscle (soleus) NAD + level in both male wild type and Lmna H222P/H222P mice. We showed that the NAD + content was significantly lowered in hearts from Lmna H222P/H222P mice at 6 months of age compared with wild type mice, when the structure of soleus was altered (symptomatic) ( Figure 6A ). We next assessed the expression level of enzymes from the salvage pathway of NAD + biosynthesis by real-time PCR using RNA extracted from Lmna H222P/H222P mouse soleus at 6 months of age. There was a significant increased Nmrk2 mRNA expression in the soleus of Lmna H222P/H222P mice compared with wild type mice ( Figure 6B ). We showed that feeding Lmna H222P/H222P mice with NR, the substrate for Nmrk2, for 2 months improved significantly RER at VO 2 peak compared with chow diet-fed mice ( Figure 6C ).
We also reported a significant difference in the maximal speed and the distance between the NR-fed and the chow diet-fed groups ( Figure 6D ). Taken together these results showed, that RER at VO 2 peak as well as physical performance are reflecting a partially restoration of the striated muscle structure and function and could therefore be used to assess future benefit of treatment in mouse model of EDMD.
DISCUSSION
There is an important need for a more comprehensive approach to evaluate the efficacy of therapeutics for neuromuscular diseases. Although traditional measures of disease pathology are useful, they have a limited functionality given that they do not assess the whole body. Muscle disease is usually assessed by histological analysis and circulating markers of myofiber injury or functional assessments of isolated muscles. Our findings strongly suggest that non-invasive protocols for assessing exercise performance in Lmna H222P/H222P mice quantifying several parameters of respiration and exercise are useful to assess the dystrophic pattern in EDMD. Exercise performance (e.g. 6 minutes walk-test) was recently used as the primary endpoint to assess the benefit of p38 inhibitor ARRY-797 (7) (9), suggesting a decreased activity of the pyruvate dehydrogenase complex and a reduced production of acetyl coenzyme A from carbohydrates. It would be interesting to extensively perform metabolomics studies in these mice to address the primary metabolic defect, which lead to decline in the function.
Assessing respiration (VO 2 and VCO 2 ) during exercise greatly increases the overall understanding of disease pathology, as it examines the combination of cardiac and skeletal muscle functions. Taken together, our study suggests that the use of respiratory performance during exercise to quantify changes in the dystrophic phenotype is a good complement to histological markers. Indeed, it can provide non-invasive markers for assessing EDMD disease progression, which is not always reflected histologically. The phenotypic changes observed in Lmna H222P/H222P mice can now be used to guide future interventional therapies to assess their beneficial effect. NR (400 mg/kg) (Chromadex), as previously reported (11) was formulated by Safe (Scientific Animal
MATERIAL AND METHODS
Mice
Lmna
Food and Engineering).
Echocardiography
Mice were anesthetized with 0.75% isoflurane in O 2 and placed in a heating pad. Transthoracic echocardiography was performed using an ACUSON 128XP/10 ultrasound with an 11 MHz transducer applied to the chest wall. All parameters were measured by a "blinded echocardiographer" unaware of the genotype or treatment of the mice, performed in 2D mode and M-mode in triplicate.
Histology
Frozen pieces of soleus and diaphragm were mounted in Tissue-Tek (Fisher Scientific) and 10 µm sections cut on a cryostat. Sections were stained with hematoxylin and eosin for histological analysis.
Representa-tive sections were photographed using a Microphot SA (Nikon) light microscope attached to a Spot RT Slide camera (Diagnostic Instruments). Images were processed using Adobe Photoshop CS (Adobe Systems).
qPCR analysis
Total RNA was extracted using the RNeasy Mini kit (Qiagen). cDNA was synthesized using the SuperScript III synthesis system according to the manufacturer's instructions (Invitrogen). Real-time qPCR reactions were performed with SYBR Green I Master mix (Roche) using with the LightCycler 480 (Roche). Relative levels of mRNA expression calculated using the ΔΔC T method were normalized by comparison to housekeeping mRNA.
NAD + concentration quantification
Fresh mouse tissues were homogenized and processed according to previous report (11) . The concentration of soleus NAD + was determined using a spectrophotometric assay as described previously (11) . Absorption measurements were carried out in 96-well plates by spectrophotometry (Tecan).
Weight and body composition
The weight of the mice and their body composition (lean mass and fat mass) were measured throughout the protocol period. For body composition we used a nuclear magnetic resonance system (LF90II, Bruker, Germany).
Evaluation of the physical performance
Each mouse was evaluated on a one-way treadmill equipped with an indirect calorimetry system (Phenomaster, TSE, Germany). The performance evaluation protocol consisted of increasing the speed by 0.01 m.s -1 every 15 seconds. Oxygen consumption (VO 2 ), carbon dioxide production (VCO 2 ) and respiratory exchange ratio (RER = VCO 2 /VO 2 ) were recorded every second. Oxygen consumption peak (VO 2 peak in ml.h -1 ) was set as the highest VO 2 value achieved during the test. We developed an algorithm based on the Savitzky-Golay principle (22) to automate the analysis of calorimetric data by smoothing the noisy data. The maximum speed reached by each mouse was recorded. The maximum speed corresponds to the speed at which the mouse can no longer run on the treadmill. All protocols were conducted for each mouse until exhaustion. Exhaustion was defined as the time when the animal "preferred" to receive electric stimulation through the grid installed at the beginning of the treadmill rather than continue the race. The intensity of the electric stimulation was 1.2 mA during 1s, with 1s latency. Before each protocol, there was a 3-minute acclimatization on the treadmill at low speeds from 0.01 to 0.05 m.s -1 . All these performance measurements were realized in the "Performance & Metabolism in Mice" facility (PMM, EA7329, Paris Descartes University, Paris, France).
Statistics
Statistical analyses were performed using GraphPad Prism software. 
